Tykerb (lapatinib) enhances the antivascular activity of Avastin (bevacizumab). There was a slide presentation at the American Society of Clinical Oncology (ASCO) Breast Cancer Symposium on September 5, 2008.
Abstract:
http://www.asco.org/ASCOv2/Meetings/...stractID=40418
Slide Presentation (large download 25.65 MB):
http://weisenthal.org/Weisenthal_ASCO.pdf